Wiener Medizinische Wochenschrift

, Volume 156, Issue 9–10, pp 255–259 | Cite as

Palliative Therapie des Glioblastoma multiforme: ein multimodales Konzept

  • Viktoria Faber
  • Ralf Thödtmann
  • Christine Marosi
Fallberichte / Case Reports
Received:
Accepted:
  • 107 Downloads

Zusammenfassung

Wir berichten über einen 72-jährigen Patienten mit einem Glioblastoma multiforme, der nach Operation mit einer Radio-/Chemotherapie (CCNU plus Ganzhirnbestrahlung 60 Gy) behandelt wurde, die allerdings auf Grund des Nebenwirkungsprofils abgebrochen werden musste. Nach einem mehrmonatigen therapiefreien Intervall wurde ein Progress der Erkrankung festgestellt, den wir mit einer etablierten Zweitlinien-Chemotherapie (Temozolomid) und gleichzeitig einem sehr begrenzten, den Patienten in seiner Lebensqualität nicht sehr beeinträchtigenden Eingriff (Rickham Reservoir) behandelten. Es konnte damit über wenige Monate eine Befundbesserung erreicht werden. Leider verstarb unser Patient 11 Monate nach Diagnosestellung wegen Progredienz. Dieser Fall zeigt, dass auch in einer palliativen Situation ein multimodaler Therapieansatz das Ziel der Behandlung, nämlich die Symptomlinderung, und damit maximale Aufrechterhaltung von Lebensqualität, erreichen kann.

Schlüsselwörter

Glioblastoma multiforme Symptome Therapie-palliative 

Palliative therapy in Glioblastoma multiforme: a multimodal concept

Summary

We report on a 72-year-old patient with a glioblastoma multiforme, who after initial operation underwent concomitant radiation (60 Gy) and chemotherapy (CCNU), which had to be stopped due to toxicity. After an interval without antineoplastic therapy lasting for several months, disease progressed. In this situation we decided to start second-line chemotherapy (Temozolomid). Because of cystic tumoural lesions an additional operative procedure was performed (Rickham reservoir). The latter had no major impact on quality of life for our patient. These procedures lead to an improvement of symptoms lasting for several months. Nevertheless our patient died 11 months after initial diagnosis due to a progression of the disease. This case report shows that multimodal therapeutic approaches should be taken into account in patients in a palliative situation.

Keywords

Glioblastoma mutliforme Therapy-palliative 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Krauseneck P, Kortmann RD, Schmoll HJ (1999) Primäre Hirntumoren bei Erwachsenen. In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Kompendium Internistische Onkologie. Springer-Verlag, Berlin, pp 475Google Scholar
  2. Huncharek M, Muscat J (1998) Treatment of recurrent high grade astrocytoma; results of a systemic review of 1,415 patients. Anticancer Res 18: 1303PubMedGoogle Scholar
  3. Roth JG, Elvidge AR (1959) Glioblastoma multiforme: A clinical survey. J Neurosurg 67: 852Google Scholar
  4. Fadul C, Wood J, Thaler H et al (1988) Morbidity and mortality of craniotomy for excision of supratentorial glioma. Neurology 38: 1374PubMedGoogle Scholar
  5. Devaux BC, O'Fallon JR, Kelly PJ (1993) Resection, biopsy and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy and outcome. J Neurosurg 78: 767PubMedCrossRefGoogle Scholar
  6. Simpson JR, Horton J, Scott C et al (1993) Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 26: 239PubMedGoogle Scholar
  7. Quigley MR, Maroon JC (1991) The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery 29: 385PubMedCrossRefGoogle Scholar
  8. Krauseneck P, Kortmann RD, Schmoll HJ (1999) Primäre Hirntumoren bei Erwachsenen. In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Kompendium Internistische Onkologie. Springer-Verlag, Berlin, pp 475–492Google Scholar
  9. Fine HA, Dear KB, Loeffler JS et al (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585PubMedCrossRefGoogle Scholar
  10. Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011PubMedCrossRefGoogle Scholar
  11. Stupp R, Dietrich PY, Ostermann KS et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20: 1375PubMedCrossRefGoogle Scholar
  12. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N Engl J Med 352: 987–996PubMedCrossRefGoogle Scholar
  13. Combs SE, Gutwein S, Schulz-Ertner D et al (2004) Temozolomide combined with radiation as first-line treatment in primary glioblastoma multiforme: phase I/II study (abstract). Proc Am Soc Clin Oncol 23: 114aGoogle Scholar
  14. Herrlinger U, Rieger J, Weller M: Phase I/II-Studie (UKT-03) zur Primärtherapie des Glioblastoms mit Strahlentherapie, CCNU und Temozolomid. www.hih-tuebingen.de/kls0.html
  15. Yung WK Prados MD, Yaya-Tur R et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group, J Clin Oncol 17: 2762PubMedGoogle Scholar
  16. Raymond E, Brandes A, Van Oosterom A et al (2004) Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup study. Proc Am Soc Clin Oncol 2004: 1501Google Scholar
  17. Brandes AA, Tosoni A, Reni M et al (2004) Second line BCNU plus CPT-11 chemotherapy in recurrent glioblastoma (GBM): Phase II study of GICNO (Italian Neuro- Oncology Group). J Clin Oncol 22: 4779PubMedCrossRefGoogle Scholar
  18. Dresemann G (2005) Imatinib (STI 571) plus Hydroxyurea. Safety and efficacy in pre-treated, progressive glioblastoma multiforme (GBM) patients (pts)-an update on the initial 30 pts. ASCO Annual MeetingGoogle Scholar
  19. Landy HJ, Feun L, Schwade JG et al (1994) Retreatment of intracranial gliomas. South Med J 87: 211PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Viktoria Faber
    • 1
  • Ralf Thödtmann
    • 1
  • Christine Marosi
    • 2
  1. 1.Abteilung für Hämatologie und Onkologie, III. Medizinische KlinikParacelsus Medizinische Privatuniversität und Salzburger LandesklinikenSalzburgAustria
  2. 2.Klinische Abteilung für OnkologieUniversitätsklinik für Innere Medizin I, Medizinische Universität WienWienAustria

Personalised recommendations